US Stocks Move | Novo Nordisk continues to rise over 2% pre-market after five consecutive gains; CICC rates it "Outperform"

Glonghui January 9th｜Novo Nordisk (NVO.US) continues to rise over 2% in pre-market trading, having previously recorded five consecutive days of gains. According to reports, CICC has given Novo Nordisk an “Outperform” rating with a target price of $73.50. The company is a global leader in metabolic diseases, with semaglutide driving growth in the GLP-1 market. The market size CAGR is expected to reach 23% from 2024 to 2030. The depth of the company’s pipeline supports future competition, with CagriSema and Amycretin expected to be launched in 2027/28, promoting an “alternating leadership” pattern. Strategic transformation into a comprehensive chronic disease platform is expected to enhance valuation premium potential.